# Tempus AI: Less Risky Buy

> Tempus AI now a higher-conviction Buy after resolving MRD ownership concerns.
- Title: Tempus AI: Less Risky Buy · Seekingalpha | Shortify
- Summary: Tempus AI now a higher-conviction Buy after resolving MRD ownership concerns. Tempus AI (TEM) is a higher-conviction Buy with positive adjusted EBITDA and xT…
- Keywords: tempus ai, mr d, x t cdx, fda approval, adjusted ebitda, 2027 pricing uplift, free cash flow, money, business, Tempus, Less, Risky
- Source: Seekingalpha — https://seekingalpha.com/article/4956999-tempus-ai-less-risky-than-when-i-said-buy
- Author: The Alpha Analyst
- Published: 2026-10-23T16:08:52+00:00
- Read time: 1 min
- Topics: tempus ai, mr d, x t cdx, fda approval, adjusted ebitda, 2027 pricing uplift, free cash flow, money, business
## Buy Rating Update
Tempus AI is now a higher-conviction Buy after resolving prior concerns on MRD ownership and cash flow.
## Personalis Acquisition
The Personalis acquisition secures MRD capabilities, integrating high-demand data and supporting pharma partnerships.
## xT CDx FDA Approval
xT CDx FDA approval enables significant pricing uplift from 2027.
## Data and Applications Growth
The Data and Applications segment maintains robust ~28% growth with a growing backlog and stabilizing margins.
## Key takeaway

Tempus AI (TEM) is a higher-conviction Buy with positive adjusted EBITDA and xT CDx FDA approval enabling pricing uplift from 2027.